Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience
- 1 April 2020
- journal article
- research article
- Vol. 24 (7), 4040-4047
- https://doi.org/10.26355/eurrev_202004_20875
Abstract
OBJECTIVE: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)-related pneumonia, referred to as COVID-19 (Coronavirus Disease 19), is a public health emergency as it carries high morbidity, mortality, and has no approved specific pharmacological treatments. In this case series, we aimed to report preliminary data obtained with anti-complement C5 therapy with eculizumab in COVID-19 patients admitted to intensive care unit (ICU) of ASL Napoli 2 Nord. PATIENTS AND METHODS: This is a case series of patients with a confirmed diagnosis of SARS-CoV2 infection and severe pneumonia or ARDS who were treated with up to 4 infusions of eculizumab as an off-label agent. Patients were also treated with anticoagulant therapy with Enoxaparin 4000 IU/day via subcutaneous injection, antiviral therapy with Lopinavir 800 mg/day + Ritonavir 200 mg/day, hydroxychloroquine 400 mg/day, ceftriaxone 2 g/day IV, vitamine C6 g/day for 4 days, and were on Non-Invasive Ventilation (NIV). RESULTS: We treated four COVID-19 patients admitted to the intensive care unit because of severe pneumonia or ARDS. All patients successfully recovered after treatment with eculizumab. Eculizumab induced a drop in inflammatory markers. Mean C Reactive Protein levels dropped from 14.6 mg/dl to 3.5 mg/dl and the mean duration of the disease was 12.8 days. CONCLUSIONS: Eculizumab has the potential to be a key player in treatment of severe cases of COVID-19. Our results support eculizumab use as an off-label treatment of COVID-19, pending confirmation from the ongoing SOLID-C19 trial.Keywords
This publication has 14 references indexed in Scilit:
- The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 PneumoniaInvestigative Radiology, 2020
- Newer Immunotherapies for the Treatment of Acute Neuromuscular Disease in the Critical Care UnitCurrent Treatment Options in Neurology, 2020
- Editorial - Novel Coronavirus 2019 (Sars-CoV2): a global emergency that needs new approaches?2020
- Editorial - Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet?2020
- Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus PathogenesismBio, 2018
- When to Stop Eculizumab in Complement-Mediated Thrombotic MicroangiopathiesAmerican Journal of Nephrology, 2018
- Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoVEmerging Microbes & Infections, 2018
- Medusa's Head: The Complement System in Traumatic Brain and Spinal Cord InjuryJournal of Neurotrauma, 2018
- The role of C5a in acute lung injury induced by highly pathogenic viral infectionsEmerging Microbes & Infections, 2015
- Plasma inflammatory cytokines and chemokines in severe acute respiratory syndromeClinical and Experimental Immunology, 2004